Now that OncotypeDX has been endorsed in ASCO guidelines, I am wondering if the next big news for this company is that the Oncotype assay is the "standard of care". Specifically, is there such a thing as "standard of care"? I mean, is there really a formal designation where one day someone (ACSO) say�s, �okay, we agree that this should be the standard of care�. Or, is �standard of care� just something that happens when a drug or assay such as Oncotype is very good and/or effective? If so, when do you all think that announcement is coming?
As someone who has witnessed breast cancer very close to home and seen OncotypeDX ordered, it seems to be a no-brainer for patients, insurance companies and Oncologists for early stage, node negative breast cancer. Is there a reason NOT to do it in these cases?
Any GHDX investors out there with any cocktail napkin calculations on future revs, versus estimates? I personally feel (and am hoping) that The Street has severely underestimated the coming earnings in future quarters as OncotypeDX spreads like wild fire. This assay is THE REAL DEAL and will save many women from the perils of chemotherapy. Lastly, in speaking with actual Oncologists, it appears MammoPrint does not present any real threat since they need fresh tissue for their assay which is not convenient or at least not always practical.
Kudos to Genomic Health and good luck to all longs.
I have only a few shares of GHDX; bought 'em in Sept @19.56, was pleased to see 24.39 on Oct 26, but haven't seen any improvement since then, just gradually down and down since then. If their product is as good as they claim, why the decrease in share value, please?
Kurt, yes the product is as good as they (and others) claim.....follow the science, not the day-to-day stock price....in the long run, the stock price will take care of itself....in the short run, there can be too much other noise